section 8.7
Safety and efficacy of HARVONI have not been established in patients with decompensated cirrhosis.
I read your post mentioning Ascites
http://www.medhelp.org/posts/Cirrhosis-of-the-Liver/hep-c-and-cirrhosis-/show/2572232
What type of doctor has prescribed Harrvoni? You should be seeing a gastroenterologist /hepatoligst experienced in decompensated cirrhosis preferably in a liver transport center Have you been told Child Turcotte Pugh (CTP) classification of the severity of cirrhosis Ascites would indicate Class B or C Do you have a MELD score?
A a gastroenterologist /hepatoligst experienced in HCV treatment with decompensated cirrhosis can best decide if Harvoni may benefit you and present the best reasons to insurance.
Best wishes for getting treatment and the best outcome .
These links will provide info on HCV treatment with decompensated cirrhosis
http://hepatitiscnewdrugs.blogspot.com/2015/04/hepatitisgileads-harvoni-and-sovaldi.html
AASLD/IDSA/IAS–USA. HCV testing and linkage to care. Recommendations for testing, managing, and treating hepatitis C.
http://www.hcvguidelines.org/full-report/unique-patient-populations-patients-decompensated-cirrhosis
accessed May 17, 2015
Patients with HCV genotype 1 or 4 with decompensated cirrhosis (moderate or severe hepatic impairment; Child Turcotte Pugh [CTP] class B or C) should be referred to a medical practitioner with expertise in that condition (ideally in a liver transplant center).
Rating: Class I, Level C
Recommended regimen for patients with decompensated cirrhosis (moderate or severe hepatic impairment; CTP class B or C) who may or may not be candidates for liver transplantation, including those with hepatocellular carcinoma. This regimen should be used only by highly experienced HCV practitioners.
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) and RBV (initial dose of 600 mg, increased as tolerated) for 12 weeks is recommended for patients with decompensated cirrhosis.
Rating: Class IIb, Level C
For patients with decompensated cirrhosis and anemia or RBV intolerance, daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) for 24 weeks is recommended.
Rating: Class IIb, Level C